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ABSTRACT 
 
 
The multiple worlds of genetically manipulated laboratory organisms such as 
transgenic mice or worms with certain gene mutations are somewhat reminiscent of 
parallel worlds in quantum mechanics. So are various models of aging tested in such 
organisms. In this context, the tumor suppressor p53 has been found to either 
accelerate or delay aging, the latter, for instance, in conjunction with ARF, another 
tumor suppressor, as shown very recently. To more easily determine which of these 
artificial settings comes closest to real life, I discuss here their features in the light of 
my protein structure-based insights that have led me to propose a physiological anti-
aging role for the retinoblastoma tumor suppressor protein (RB) over the past four 
years.
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About two years ago, Serrano and coworkers reported that premalignant 
experimental tumors display features of senescence (1). The authors presented this 
induction of cellular aging as a defense mechanism mounted by the host in response 
to an oncogene-initiated neoplastic transformation (1). In this context, these 
investigators also qualified the tumor suppressor p53 as an "oncogene-induced 
senescence effector" (1). As such, this study supported the widely held view according 
to which the processes of cancer and aging exclude one another or yet that the sense 
of aging is to oppose the occurrence of neoplasias (2). 
This month, however, Serrano et al. (3) communicated results that contradict 
the alleged dichotomy between senescence and cancer, yet they failed to quote their 
own paper of 2005 and explained the obvious data contradiction by different 
experimental conditions. Specifically, these investigators attributed those previous 
cases in which p53 had previously been found to accelerate aging to its "permanent 
activation" (3)- due to "truncation of p53 domains or constitutive endogenous 
damage" (3)- whereas their own results of this month led them to assume that 
increasing the activity of ("normally regulated") p53 produces delayed aging (3). 
Moreover, they showed data implying that p53 cooperates with ARF, which is another 
important tumor suppressor, in delaying aging (3). 
Yet, these interpretations per se cannot solve the underlying puzzle as to which 
of the discussed observations on p53 is ultimately correct in terms of reflecting 
normal physiology since all of them are based on data obtained with genetically 
manipulated and thus abnormal mice. It follows that, by definition, p53 or any other 
gene product cannot be "normally regulated" in such animals. Nevertheless, some of 
these models may represent an useful approximation of biological events in real life, 
but in order to determine which of these models complies with reality one needs to 
take into account additional considerations. 
In 2003, I derived a novel concept on a dual inhibition of cancer and aging 
from my identification of a sequence in the aminoterminus of retinoblastoma protein 
(RB) predicting that this tumor suppressor may antagonize the complex formation 
between insulin and its receptor (4). Since Kenyon and coworkers had found that 
insulin´s activation of its receptor may contribute to accelerating aging (5), I 
concluded that, conversely, an interference of RB with the physical interaction 
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between insulin and its receptor may counteract, besides neoplastic transformation, 
also the process of senescence in entire organisms (4). 
Subsequently, I detected similarities between the amino acid sequences of RB 
and the anti-aging protein Klotho, thus reinforcing my concept on an anti-aging role 
of RB and also assigning a possible tumor suppressor role to Klotho (6). 
Interestingly, these previous publications of mine suggesting a connection 
between the functions of tumor suppression and anti-aging were echoed in part by 
the 2006 report by Kenyon and coworkers who demonstrated that worms with 
certain insulin receptor gene mutations display both an increased life span and an 
augmented resistance towards tumor formation (7). 
Predictably, however, this worm model cannot entirely reflect equivalent 
phenomena in higher eukaryotes since the latter organisms have developed 
compensatory mechanisms to circumvent aberrancies in insulin signal transduction 
arising from a dysfunction of the insulin receptor. Based on this knowledge, an 
alternative model of aging involving an hyperinsulinemia secondary to insulin 
receptor defects and the subsequent interaction of insulin with retinoblastoma 
protein in the cell nucleus was presented (8). 
I then tied together my own perception of aging (8) with the Kenyon concept 
on senescence to propose in an unifying framework that, in both aging models, 
retinoblastoma protein is being inactivated: in the first case, due to the binding of 
insulin to RB and, in the second case, through RB hyper-phosphorylation following 
the phosphorylation cascade elicited by insulin receptor activation (9). 
This framework should help establish the roles of p53 and ARF in natural 
senescence. Given that it is known that RB acts as a downstream effector for both p53 
(10,11) and ARF (12) to inhibit cell cycle progression and, as a result, to prevent 
cancer, it is conceivable that the anti-aging effects of p53 and ARF now observed in 
experimental models (1) have been mediated by RB, thus lending further support to 
the notion that RB is not only the key checkpoint in the control of cancer, but also of 
aging (9). Since cancer occurs predominantly in older individuals, my present 
molecular insight should significantly contribute to implementing the clinical 
rationale of reducing the incidence of malignancies by promoting longevity. 
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